Spurred on by these insights, the company set its sights on the development of different technologies that could stimulate an antitumor response or address tumor-related immunosuppression—a combined effort that could provide the greatest chance of treatment success.
NewLink Genetics is now a publicly traded company of over 100 employees on the verge of bringing new cancer immunotherapies to physicians and patients. In addition to the core group of scientists, some of whom came from the National Cancer Institute, seasoned professionals in product development, marketing, regulatory affairs, and manufacturing are in place to help lead NewLink Genetics toward the launch of its first commercial product.
NewLink Genetics is based in Ames, Iowa, because of its Midwestern culture and values, as well as the competitive advantage of having easy access to a highly trained, stable work force. NewLink Genetics is located in Iowa State University Research Park, putting them in close proximity to top-rated chemistry programs, graduate students, and other resources. In the near future, NewLink Genetics plans to expand its commercial operations.[/td_text_with_title]